Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BrILliance: REGN10597 Alone or With Cemiplimab in Advanced Solid Tumors
NCT06413680Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Feb 2030
- Modality
- Immunomodulatory ADCs, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of REGN10597 in melanoma, clear cell renal cell carcinoma (ccRCC), solid tumor, sponsored by Regeneron Pharmaceuticals. Started Sep 2024; status: recruiting.
02
Drugs
REGN10597
03
Conditions
melanomaclear cell renal cell carcinoma (ccRCC)solid tumor
Beyond the preview
Go deeper on NCT06413680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413680.